New hope for rare vasculitis: rituximab may outperform standard therapy
NCT ID NCT03164473
First seen Nov 20, 2025 · Last updated May 21, 2026 · Updated 27 times
Summary
This study tested whether rituximab is better than azathioprine at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. 98 adults with newly-diagnosed or relapsing EGPA who had already achieved remission took part. The goal was to see which drug helped patients stay symptom-free longer while reducing steroid use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, Paris, 75014, France
Conditions
Explore the condition pages connected to this study.